Compare REKR & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REKR | ONCY |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Pharmaceuticals and Biotechnology |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 98.7M |
| IPO Year | 2017 | 2002 |
| Metric | REKR | ONCY |
|---|---|---|
| Price | $0.71 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,234,000.00 | N/A |
| Revenue This Year | $12.51 | N/A |
| Revenue Next Year | $23.49 | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $0.56 |
| 52 Week High | $3.42 | $1.51 |
| Indicator | REKR | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 56.31 |
| Support Level | $0.70 | $0.94 |
| Resistance Level | $0.92 | $1.14 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 18.78 | 41.60 |
Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.